ISORAY, INC. (NYSEMKT:ISR) Files An 8-K Submission of Matters to a Vote of Security Holders
|Submission of Matters to a Vote of Security Holders|
On December 14, 2016, IsoRay, Inc. (IsoRay or the Company) held
its Fiscal 2017 Annual Meeting of Shareholders, where three
proposals were voted on. The proposals are described in detail in
IsoRays definitive proxy statement filed with the Securities and
Exchange Commission on November 4, 2016. Of the 55,076,484 common
and preferred shares outstanding and entitled to vote at the
Annual Meeting, 40,495,156 common and preferred shares (or
73.53%), constituting a quorum, were represented in person or by
proxy at the Annual Meeting.
The final voting results on each proposal are set forth below.
Proposal 1. The shareholders elected four directors to the
board of directors to serve until the fiscal 2018 annual meeting
of shareholders. The votes for this proposal were:
|Thomas C. LaVoy||8,491,546||1,483,524||30,520,086|
|Philip J. Vitale, M.D||8,460,088||1,514,982||30,520,086|
|Michael W. McCormick||8,405,102||1,569,968||30,520,086|
Proposal 2. The shareholders ratified the appointment of
DeCoria, Maichel Teague, P.S. as IsoRays independent registered
public accounting firm for the fiscal year ending June 30, 2017.
The votes on this proposal were:
Proposal 3. The shareholders approved, on an advisory
basis, the compensation of IsoRays named executive officers. The
votes on this proposal were:
About ISORAY, INC. (NYSEMKT:ISR)
IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company’s Proxcelan Cesium-131 seed is classified as a Class II device. ISORAY, INC. (NYSEMKT:ISR) Recent Trading Information
ISORAY, INC. (NYSEMKT:ISR) closed its last trading session up +0.019 at 0.579 with 55,553 shares trading hands.